$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Can F/TAF be used as PrEP prophylaxis? Safety of use and scope of application
2026-02-01 22:25:32
Check Details
Febuxostat (Febuxostat) side effects and potential hazards and safety reminders when taking it
2026-02-01 22:25:32
Check Details
Which alternative drugs should be chosen for treatment after furmonertinib resistance?
2026-02-01 22:25:32
Check Details
Can ensifentrine-Ohtuvayre be purchased through formal channels in China and purchase advice?
2026-02-01 22:25:32
Check Details
Detailed introduction to the side effects of Roaccutane (isotretinoin) on women and their prevention and response methods
2026-02-01 22:25:32
Check Details
Will doxorubicin cause hair loss when used? Probability of side effects and prevention methods
2026-02-01 22:25:32
Check Details
Can I stop taking Everolimus (Afinitor) at will after taking it?
2026-02-01 22:25:32
Check Details
Detailed description of the main indications and patient scope of estramustine (Adelex)
2026-02-01 22:25:32
Check Details
What is the approximate cost estimate for one month’s treatment with Seripase (BRINEURA)?
2026-02-01 22:25:32
Check Details
How to buy Eslicarbazepine, regular channels and precautions
2026-02-01 22:25:32
Check Details
Remibrutinib-RHAPSIDO instruction manual in Chinese
2026-02-01 22:25:32
Check Details
Is Nintedanib/Vigat a life-saving drug or a potentially harmful drug?
2026-02-01 22:25:32
Check Details
1
2
...
2170
2171
2172
2173
2174
2175
2176
...
10227
10228
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Gilteritinib (XOSPATA): Dosing Cycle, Treatment Duration, and Development Background
2
Dabrafenib (TAFINLAR): Indications, Adverse Effect Management, and Dose Modification Guide
3
Adagrasib (Krazati): A Complete Guide to Side-Effect Recognition and Grade-Based Management
4
Tepotinib (TEPMETKO): Complete Dosing, Side-Effect Management, and Discontinuation Guide
5
Valganciclovir (Valcyte) in Post-Transplant CMV Management: A Comprehensive Guide
6
Tivozanib Dosage and Administration: Standard Dosing, Cycle Schedule, and Hepatic Impairment Adjustments
7
Long-Term Anagrelide Use: Common Adverse Effects and Key Monitoring Considerations
8
Resmetirom Indication Clarification: Approved for NASH Fibrosis, Not Hepatitis B Cirrhosis
9
Vemurafenib: Mechanism of Action and Clinical Role in BRAF V600E–Targeted Therapy
10
Anagrelide vs. Hydroxyurea in Essential Thrombocythemia: Efficacy Profiles and Clinical Positioning
11
SCEMBLIX (Asciminib) Side Effect Management & Special Population Guide
12
Sabril (Vigabatrin) Explained: Indications, Vision Loss Risk & Key Warnings